Mallinckrodt raised Ofirmev price by 140%, says Piper Jaffray Piper Jaffray says that according to Price Rx, Mallinckrodt (MNK) implemented a 140% price increase for Ofirmev on May 15. Piper views the increase as larger than expected and says it significantly reduces the risk to shares should Fresenius (FMS) launch its Ofirmev generic over the next two years. Piper thinks the risk/reward on shares of Mallinckrodt is compelling and it reiterates an Overweight rating on the stock.
Mallinckrodt board approves share repurchase program Mallinckrodt announced that its board has approved a share repurchase program. The open-ended authorization permits the company to repurchase up to $300 million of Mallinckrodt ordinary shares.